PFEPfizer (PFE) is moving in a clear uptrend, forming higher lows along the rising trendline.
A good entry level is around $26, where price may retest the trendline before moving higher.
The main target is $30, which represents strong horizontal resistance.
The stop loss at $23 protects the trade, as a
Pfizer Inc Shs Cert Deposito Arg Repr 0.25 Shs
No trades
Key facts today
Pfizer plans to cut its Swiss workforce from 300 to 70 by year-end, eliminating over 200 jobs as part of a cost-saving initiative targeting $7.7 billion by 2027.
Pfizer has teamed up with Yao Pharma to create an oral weight-loss drug, investing $150 million upfront and up to $1.9 billion in potential milestone payments.
Pfizer's Phase 3 HER2CLIMB-05 trial showed TUKYSA combined with trastuzumab and pertuzumab cut disease progression or death risk by 36% versus trastuzumab and pertuzumab alone.
0.37 USD
7.12 B USD
56.51 B USD
About Pfizer, Inc.
Sector
Industry
CEO
Albert Bourla
Website
Headquarters
New York
Founded
1849
ISIN
ARDEUT111424
FIGI
BBG000HG7NC4
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Related stocks
Pfizer (PFE)Pfizer (PFE) – Technical Structure Suggests a Broad Rounded Bottom Formation
Pfizer continues to develop a large, multi-month rounded bottom structure on the daily chart. The price action since late 2023 shows three distinct and symmetrical troughs around the 25–26 zone, forming a wide Rounded Trip
Pfizer (PFE) – Hedged Covered Call Income CampaignAfter Pfizer’s return to price levels closer to its pre-COVID range, I personally believe the stock is undervalued relative to its current earnings profile and long-term potential. This view is also influenced by Pfizer’s recent acquisition of Metsera, which brings a pipeline of obesity and cardiome
Pfizer stock exploded as expected from weekly demandPfizer just did it again!
After weeks of sleeping inside that weekly demand imbalance, the pharmaceutical giant exploded — exactly as expected from our supply and demand forecast. Price has already rallied more than 7%, proving once again how powerful these imbalances can be when you learn to read
Dividend Dose & Breakout BouncePfizer has developed an interesting technical setup: the stock is currently holding above a gap around $23.50, and a breakout above $26.50 could pave the way toward the $27.69 resistance level. With a stop‑loss placed at $23.58, this trade presents a strong risk‑to‑reward ratio.
From a fundamental
PFE QuantSignals V3 Earnings 2025-11-03PFE QuantSignals V3 Earnings 2025-11-03
PFE Earnings Signal | 2025-11-03
• Direction: BUY CALLS | Confidence: 72%
• Entry Plan: Open | Expiry 2025-11-07
• Strike Focus: $24.50
• Entry Range: $0.47
• Target 1: $0.94
• Stop Loss: $0.28
• Implied Move: $1.12 (4.6%)
• 24h Move: +0.06%
• Flow Intel: Bull
Pfizer “shows its claws”: between litigation&boost searchPfizer “shows its claws”: between litigation and the search for a new boost
By Ion Jauregui – Analyst at ActivTrades
Pfizer (NYSE: PFE) is back in Wall Street’s spotlight after filing a lawsuit against Metsera (NASDAQ: MTSR) and Novo Nordisk (CPH: NOVOb), accusing them of breaching a merger agr
Pfizer’s $PFE Demand Zone — Ready to Explode?Hey traders, it’s Alfonso Moreno from Set and Forget! Today, I’m diving into one of the most famous pharmaceutical giants on the planet — Pfizer. Yes, that Pfizer. Love them or hate them, the chart doesn’t lie. The weekly timeframe just gave us a brand-new demand imbalance, and it’s looking ready to
Back test before continuationNYSE:PFE after breaking out on trump deal and now working with him to sell their products through TrumpRx launching next year. They are also exempt from tariffs for 3 years and plan to invest 60B in the US. good support/resistance flip could take place here would like to hold 25 but 24 is possible.
Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience?Pfizer (PFE): Undervalued Pharma Giant Amid #Economy Resilience? $28.90 in Sight? 📈
At $24.04 (+0.04%), PFE offers a compelling entry with its low P/E of 12.72 and robust 7.15% dividend yield, trading well below analyst targets of $28.90 (20% upside potential)—could resilient economic forecasts boo
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
P
PFE5588844
Pfizer Investment Enterprises Pte. Ltd. 5.34% 19-MAY-2063Yield to maturity
5.77%
Maturity date
May 19, 2063
P
PFE5588843
Pfizer Investment Enterprises Pte. Ltd. 5.3% 19-MAY-2053Yield to maturity
5.61%
Maturity date
May 19, 2053
P
PFE5588591
Pfizer Investment Enterprises Pte. Ltd. 5.11% 19-MAY-2043Yield to maturity
5.41%
Maturity date
May 19, 2043
See all PFEC bonds
Curated watchlists where PFEC is featured.
















